menu
    • menu
    [{"orgOrder":0,"company":"Syncromune","sponsor":"Eucure Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"YH002","moa":"OX40L receptor (CD134)","graph1":"Oncology","graph2":"Phase I","graph3":"Syncromune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syncromune \/ Syncromune","highestDevelopmentStatusID":"6","companyTruncated":"Syncromune \/ Syncromune"},{"orgOrder":0,"company":"Syncromune","sponsor":"Syncromune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SV-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Syncromune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syncromune \/ Syncromune","highestDevelopmentStatusID":"6","companyTruncated":"Syncromune \/ Syncromune"},{"orgOrder":0,"company":"Syncromune","sponsor":"Syncromune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SV-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Syncromune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syncromune \/ Syncromune","highestDevelopmentStatusID":"6","companyTruncated":"Syncromune \/ Syncromune"},{"orgOrder":0,"company":"Syncromune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"SV-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Syncromune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syncromune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Syncromune \/ Undisclosed"},{"orgOrder":0,"company":"Syncromune","sponsor":"Williams Cancer Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"SV-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Syncromune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syncromune \/ Williams Cancer Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Syncromune \/ Williams Cancer Foundation"},{"orgOrder":0,"company":"Syncromune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"SV-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Syncromune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syncromune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Syncromune \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Syncromune

    Menu

    Syncromune

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Syncromune

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Syncromune

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SV-102

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

                            Details : SV-102 is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            August 01, 2024

                            Lead Product(s) : SV-102

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Syncromune

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Syncromune

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SV-102

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Williams Cancer Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Syncromune Granted FDA Fast-Track for SYNC-T SV-102 for Metastatic Prostate Cancer

                            Details : SV-102 is an investigational vaccine utilising compamy's innovative SYNC-T platform, given as intratumoral infusion, for the treatment of metastatic castrate-resistant prostate cancer.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            July 01, 2024

                            Lead Product(s) : SV-102

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Williams Cancer Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Syncromune

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Syncromune

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SV-102

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Syncromune Receives FDA IND Clearance for SYNC-T SV-102 in Prostate Cancer

                            Details : SYNC-T SV-102 therapy combines partial tumor oncolysis with a fixed-dose combination multi-target biologic drug, a personalized therapeutic approach for metastatic castrate-resistant prostate cancer.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            May 30, 2024

                            Lead Product(s) : SV-102

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Syncromune

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Syncromune

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YH002

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Eucure Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40 Antibody (YH002) and Multiple Acti...

                            Details : Under the terms of the agreement, Syncromune will acquire exclusive worldwide rights for development and commercialization of the intratumoral combination therapy containing Eucure’s YH002, and multiple other active ingredients as part of the Syncrovax...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            October 17, 2022

                            Lead Product(s) : YH002

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Eucure Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Syncromune

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Syncromune

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SV-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Williams Cancer Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors

                            Details : SV-101 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 16, 2022

                            Lead Product(s) : SV-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Williams Cancer Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Syncromune

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Syncromune

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SV-102

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Williams Cancer Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer

                            Details : SV-102 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 16, 2022

                            Lead Product(s) : SV-102

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Williams Cancer Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth